Plant Summary
Plant Information
TCMBank_ID: | TCMBANKHE006408 |
ID: | TCMBANKHE006408 |
植物拉丁名: |
|
功能与主治: | To clear damp heat, resolve toxin and disperse swelling, quicken blood and relieve pain./Damp-heat diarrhea dysentery, mammary welling abscess, hemorrhoids, toxin swelling of sores, knocks and falls, fracture, bleeding due to external injury. |
药用植物名: | 黄花稔 |
药用部位: | leaf or root |
TCM_ID_id: | 8165 |
植物对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN035866 | (4S,5S)-4-hydroxy-5-pentyloxolan-2-one | (4S,5S)-4-hydroxy-5-pentyl-tetrahydrofuran-2-one; (4S,5S)-4-hydroxy-5-pentyl-oxolan-2-one; (4S,5S)-4-hydroxy-5-pentyl-2-tetrahydrofuranone; (4S,5S)-5-amyl-4-hydroxy-tetrahydrofuran-2-one | 172.25 | ||
| TCMBANKIN040983 | anticancer lignan pmv70p691-124 | C20H20O7 | COC1=C(C=CC(=C1)C2C3COC(C3C(=O)O2)C4=CC(=C(C=C4)O)OC)O | ||
| TCMBANKIN041046 | Anticancer Alkaloid PMV70P691-050 | ||||
| TCMBANKIN041933 | anticancer benzenoid pmv70p691-58 | C10H12O4 | CC(C(=O)C1=CC(=C(C=C1)O)OC)O | ||
| TCMBANKIN047327 | Anticancer Alkaloid PMV70P691-051 | ||||
| TCMBANKIN050040 | Cryptolepinone | 248.28 g/mol | |||
| TCMBANKIN059078 | Psi-ephedrin | (1S,2S)-(+)-Pseudoephedrine; AIDS-011904; (1S,2S)-2-Methylamino-1-phenyl-1-propanol; PDSP1_001347; Pseudoephedrinum [INN-Latin]; KBioGR_001763; KBio2_003926; L(+)-psi-Ephedrine; (1S,2S)-Pseudoephedrine, polymer-bound; IDI1_000451; (1S,2S)-()-Pseudoephedrine; NCGC00015408-01; 649031_ALDRICH; Spectrum2_001303; PSEUDOEPHEDRINE; Pseudoefedrina [INN-Spanish]; Pseudoephedrine, (+)-; Isoephedrine; Spectrum4_001162; 82545_FLUKA; Lopac-E-3250; NINDS_000451; 304-87-0; ()-psi-Ephedrine; d-Pseudoephedrine; (+)-(1S,2S)-Pseudoephedrine; (+)-psi-Ephedrine; KBio3_002762; (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)- (9CI); Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))-; 30987-59-8; C02765; (1S,2S)-Pseudoephedrine; alpha-(1-(Methylamino)ethyl)benzyl alcohol; (+)-threo-Ephedrine; Psi-ephedrine; L-(+)-Pseudoephedrine; 287636_ALDRICH; (+)-Pseudoephedrine; KBioSS_001358; HSDB 3177; psi-Ephedrine, (+)-; BB_NC-1383; (1S,2S)-2-methylamino-1-phenyl-propan-1-ol; (1S,2S)-2-methylamino-1-phenylpropan-1-ol; Spectrum_000878; AIDS011904; (1S,2S)-()-2-Methylamino-1-phenyl-1-propanol; KBio1_000451; ()-Pseudoephedrine; Pseudoephedrine (D); trans-Ephedrine; KBio2_006494; Pseudoephedrine, L-(+)-; alpha-(1-Methylaminoethyl)benzyl alcohol; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)-; DivK1c_000451; d-psi-Ephedrine; 90-82-4; 37577-31-4; Spectrum3_001771; BSPBio_003261; SPBio_001365; Spectrum5_000650; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alphaS)-; EINECS 202-018-6; d-psi-2-Methylamino-1-phenyl-1-propanol; d-Isoephedrine; KBio2_001358; NCI60_002955;d-pseudoephedrine;(+)pseudoephedrine;ephedine;1-ephedrine;l-Pseudoephedrine;pseudoephedrine;Eciphin;ephedrine;AC1Q3XJM; (-)-(1R,2R)-Pseudoephedrine; EC 206-292-8; (-)-; (1r,2r)-pseudoephedrine; Pseudoephedrine, (-)-; (R-(R*,R*))-alpha-(1-(Methylamino)ethyl)benzyl alcohol; CHEMBL2110905; (+)-EPHEDRINE HYDROCHLORIDE; Opera_ID_462; (1R,2R)-2-Methylamino-1-phenyl-1-propanol; C-33392; LS-125921; (-)-threo-Ephedrine; (1R 2R)-(-)-PSEUDOEPHEDRINE; l-(1R,2R)-Pseudoephedrine; FT-0771224; (1R,2R)-2-(methylamino)-1-phenyl-propan-1-ol; Benzenemethanol, alpha-((1R)-1-(methylamino)ethyl)-, (alphaR)-; (-)-Pseudoephedrine 1.0 mg/ml in Methanol; MLS000069657; D(-)-Pseudoephedrine; DTXSID90185895; (1R,2R)-(-)-2-(Methylamino)-1-phenylpropanol; AC1L1Y3M; AC1Q3XJN; (1R,2R)-(-)-Pseudoephedrine; S76J9U46ST; (-)-psi-Ephedrine; Benzenemethanol, alpha-(1-;(-)-(1R,2R)-Pseudoephedrine; (R-(R*,R*))-alpha-(1-(Methylamino)ethyl)benzyl alcohol; Pseudoephedrine, (-)-; (1R,2R)-2-Methylamino-1-phenyl-1-propanol; (-)-threo-Ephedrine; (1R,2R)-(−)-Pseudoephedrine; 287644_ALDRICH; l-(1R,2R)-Pseudoephedrine; Benzenemethanol, alpha-((1R)-1-(methylamino)ethyl)-, (alphaR)-; (1R,2R)-2-methylamino-1-phenylpropan-1-ol; MLS000069657; (1R,2R)-2-methylamino-1-phenyl-propan-1-ol; (1R,2R)-(-)-Pseudoephedrine; (-)-psi-Ephedrine; Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (R-(R*,R*))-; CPDD 0049; D-(-)-Pseudoephedrine; (1R,2R)-Ephedrine; (-)-Pseudoephedrine; (−)-Pseudoephedrine; SMR000059174; (1R,2R)-(−)-2-(Methylamino)-1-phenylpropanol; PDSP1_001343; (−)-psi-Ephedrine; 7009-81-6; PDSP1_001346; EINECS 206-292-8; 82547_FLUKA;Symptom 2; Dimetapp Decongestant; AK402032; CoAdvil; 1S,2S-(+)-Pseudoephedrine hydrochloride; Pseudoephedrine, (+)-; (1S,2S)-2-(1/4)x degrees +/->>u-1-+/-(1/2)+/-u (1/4) NIEaNI; PSEUDOEPHEDRINE HYDROCHLORIDE; Dorcol; MLS001304069; BG00603638; Rhinalair; EC 206-462-1; Efidac 24 Pseudoephedrine Hcl; d-I+/-Ae>>AE(1/4)i NIEaNI; SCHEMBL33285; AKOS027383893; NSC-106567; (+)-Pseudoephedrine hydrochloride, >=98%; NSC33634; Benzenemethanol, alpha-(1-(methylamino)ethyl)-, hydrochloride, (S-(R*,R*))- (9CI); Topcare 12 hour decongestant; Actifed Sinus Daytime; Isoephedrine Hydrochloride; (+)-Pseudoephedrine hydrochloride, Sigma Reference Standard; CPDD 0050; (1S,2S)-2-(Methylamino)-1-phenyl-1-propanol Hydrochloride; HMS1920N04; Pseudoephedrine hydrochloride [USAN]; NSC759616; (+)-; 345-78-8; AN-23411; D-(alpha-(1-Methylamino)ethyl)benzyl alcohol hydrochloride; d-Pseudoephedrine hydrochloride; API0003970; Pharmakon1600-01500516; SPECTRUM1500516; Pseudoephedrine hydrochloride, British Pharmacopoeia (BP) Reference Standard; psi-Ephedrine Hydrochloride; (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol hydrochloride; P1654; Sudomyl; Sudafed 12 Hour; Contac Day & Night Allergy Sinus Day Caplets; x-Ae>>AE(1/4)i NIEaNI; Sudafed Liquid, Children's; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, hydrochloride (1:1), (alphaS)-; Pseudoephedrine, L-(+)-; Benzenemethanol, hydrochloride, [S-(R*,R*)]-; NSC-759616; D00485; Sudafed 24 Hour; Pseudoephedrine hydrochloride [USAN:USP]; Ornex and Maximum Strength Ornex; (+)-Pseudoephedrine Hydrochloride 1.0 mg/ml in Methanol (as free base); 345P788; LS-125924; Sine-Off Maximum Strength No Drowsiness Formula Caplets; CHEMBL1200724; NSC 33634; Tylenol Sinus Medication, Maximum Strength; Suphedrine; Deconsal II; D-[.alpha.-(1-Methylamino)ethyl]benzyl alcohol hydrochloride; Pseudoephedrine hydrochloride (USP); Benzenemethanol, alpha-(1-(methylamino)ethyl)-, hydrochloride, (S-(R*,R*))-; Sudafed (TN); (+)-Pseudoephedrine hydrochloride; 56979-55-6; UNII-6V9V2RYJ8N; CHEBI:8604; (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol;hydrochloride; Histalet Syrup; L-(+)-Pseudoephedrine hydrochloride; NSC-33634; Sun mark sinus; AC1L1TCY; C10H15NO.HCl; Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))-, hydrochloride; Pseudoephedrine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material; Tussaphed; Nexafed; Benzenemethanol, alpha-(1-(methylamino)ethyl)-, hydrochloride, (S-(theta,theta))-; First sign; L(+)-Pseudoephedrine hydrochloride; NSC106567; W-106727; Sinufed; Benzenemethanol, hydrochloride, S-(R,R)-; Pseudoephedrine, hydrochloride, L-(+)-; SMR000718787; Otrinol; Pseudoephedrine hydrochloride, European Pharmacopoeia (EP) Reference Standard; Pseudoephedrine Hcl; CCG-39241; NSC 106567; (1S,2S)-2-(methylamino)-1-phenyl-propan-1-ol hydrochloride; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, hydrochloride, (alphaS)-; Novafed; Besan; BB_NC-1383; Sudafed hydrochloride; WLN: QYR & Y1 & M1 & GH-L; C-09673; Pseudophedrine hydrochloride; 6272-89-5; 6V9V2RYJ8N; PediaCare Decongestant Drops; d-OiAe>>AE(1/4)i NIEaNI; BALXUFOVQVENIU-KXNXZCPBSA-N; EINECS 206-462-1; Pseudoephedrine hydrochloride, United States Pharmacopeia (USP) Reference Standard;PDSP2_001330; (1R,2S)-(-)-2-Methylamino-1-phenyl-1-propanol; AIDS002645; (-)-Ephedrine; Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (R-(R*,S*))-; (1R,2S)-(−)-2-Methylamino-1-phenyl-1-propanol; 1-alpha-(1-Methylaminoethyl)benzyl alcohol; Ephedrine l-form; Ephedrine [USAN:BAN]; 134-72-5(SULFATE 2:1); 50-98-6 (HYDROCHLORIDE); C01575; 45261_FLUKA; D00124; L-(-)-Ephedrine; Ephedremal; (1R,2S)-(-)-alpha-(1-Methylaminoethyl)benzenemethanol; (1R,2S)-(−)-Ephedrine; NSC 170951; CHEBI:15407; (1R,2S)-2-methylamino-1-phenyl-propan-1-ol; Ephedral; AIDS-002645; Ephedrine (TN); 50906-05-3 (HEMIHYDRATE); AI3-02761; 134910_ALDRICH; L-Ephedrine; Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (-)-; Ephedrine; NSC 8971; (1R,2S)-2-methylamino-1-phenylpropan-1-ol; 6912-63-6; 6912-63-6 (DELETED); HSDB 3072; (1R,2S)-2-Methylamino-1-phenyl-1-propanol; Ephedrine (USP); (−)-Ephedrine; EINECS 206-080-5; alpha-Hydroxy-beta-methyl amine propylbenzene; L-erythro-2-(methylamino)-1-phenylpropan-1-ol; 1-Phenyl-1-hydroxy-2-methylaminopropane; 2-Methylamino-1-phenyl-1-propanol; PDSP2_001327; alpha-Hydroxy-beta-methylaminopropylbenzene; (L)-EPHEDRINE; 1-2-Methylamino-1-phenylpropanol; l-alpha-(1-Methylaminoethyl)benzyl alcohol; (1R,2S)-(−)-alpha-(1-Methylaminoethyl)benzyl alcohol; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alphaR)-; (-)-alpha-(1-Methylaminoethyl)benzyl alcohol; 1-Sedrin; 321-96-0; Lopac0_000501; (1R,2S)-1-phenyl-1-hydroxy-2-methylaminopropane; alpha-(1-(Methylamino)ethyl)benzenemethanol; 321-96-0 (DELETED); 299-42-3; (1R,2S)-2-(methylamino)-1-phenylpropan-1-ol; Biophedrin;SCHEMBL8098202; CHEMBL1620154; ephedrine ; (s)-2-methylamino-1-phenylpropan-1-ol; (1S)-1-Phenyl-2-(methylamino)-1-propanol | C10H15NO | 165.23 | CC(C(C1=CC=CC=C1)O)NC |
| TCMBANKIN059884 | blumenol a | C13H20O3 | 224.3 g/mol | CC1=CC(=O)CC(C1(C=CC(C)O)O)(C)C | |
| TCMBANKIN061528 | scopoletin | NINDS_000720; 7-hydroxy-6-methoxy-coumarin; NCGC00016349-05; 6-methoxy-7-hydroxycoumarin; 6-methoxy-7-oxidanyl-chromen-2-one; CHEBI:17488; SPBio_002884; HMS1571A05; RODXRVNMMDRFIK-UHFFFAOYSA-N; NCGC00016349-08; TR-029034; 5-18-03-00203 (Beilstein Handbook Reference); Acid, Gelseminic; 6-Methylesculetin; UNII-KLF1HS0SXJ; 7-hydroxy 6-methoxy coumarine; Scopoletin, >=99%; AB00443525; beta -methylesculetin; CS-5791; BRN 0156296; NCGC00094973-02; SR-01000841273-4; HMS2268G04; SCHEMBL147702; scopoletin ; Prestwick3_000962; CHEMBL71851; Escopoletin; Spectrum2_001207; HMS2098A05; NCGC00016349-07; NCGC00094973-03; Murrayetin; 7-Hydroxy-6-methoxy-2H-1-benzopyran-2-one; Bio-0208; NCGC00016349-02; Prestwick2_000962; ZB002243; BG01509594; NCGC00016349-03; BPBio1_001061; Scopoletin, analytical standard; AX8035441; 0B4B9FAA-686D-4977-AA08-65F8E4F1977C; BRD-K96163925-001-06-5; ZX-AN021883; FCH1115349; AC1NQX27; 7-hydroxy-6-methoxy-chromen-2-one; KBio3_002444; DTXSID0075368; 7-Hydroxy-5-methoxycoumarin; SC-90283; ST24045669; b-Methylaesculetin; KBioGR_001348; 7-Hydroxy-6-methoxy-2H-chromen-2-one #; Gelseminic acid; ZX-AFC000681; S0367; MLS002154074; 4CN-0905; 6-O-Methylesculetin; HMS502D22; KLF1HS0SXJ; MCULE-6077230919; MLS002472878; IDI1_000720; SPECTRUM1502242; Aesculetin 6-methyl ether; C-30831; MFCD00006872; Scopoletol; Buxuletin; AB0019688; CC-34387; Chrysotropic Acid; RTR-029034; ACon1_000143; CCRIS 3592; 6-Methoxyumbelliferone; LS-55217; NSC-405647; NSC 405647; 6-Methoxy-7-hydroxycoumarin; Esculetin-6-methyl ether; BDBM50156693; ZX-AT021192; AK111291; Scopoletin, United States Pharmacopeia (USP) Reference Standard; 7-Hydroxy-6-methoxy-2H-chromen-2-one; I14-14171; Prestwick1_000962; PubChem15777; MolPort-000-707-493; DivK1c_000720; A844290; AN-42608; NCGC00016349-04; ST056287; ZINC57733; BSPBio_002944; Chrysatropic acid; NCI60_003834; CAS-92-61-5; Acid, Chrysotropic; NSC405647; SR-01000841273; Prestwick0_000962; BSPBio_000963; KBio1_000720; FT-0631451; beta-Methylesculetin; Spectrum4_001054; SR-01000841273-3; AJ-09778; 7-Hydroxy-6-methoxycoumarin; W-3522; MEGxp0_001192; HY-N0342; NCGC00016349-06; Scopoletine; 7-hydroxy-6-methoxy-1-benzopyran-2-one; 006S872; OR22352; S-2000; NCGC00094973-01; EINECS 202-171-9; TNP00096; KS-00000YGS; Spectrum5_000654; Spectrum3_001532; TD8126; 2H-1-Benzopyran-2-one, 7-hydroxy-6-methoxy- (9CI); SPBio_000994; AKOS000277133; COUMARIN, 7-HYDROXY-6-METHOXY-; 2H-1-Benzopyran-2-one, 7-hydroxy-6-methoxy-; SMR000112541; BIDD:PXR0125; CCG-39140; Esculetin 6-methyl ether; D05QOR; 92-61-5; ALBB-023369; 7-hydroxy-6-methoxychromen-2-one; C01752; BIS1402; HMS1921N16; KB-249948; .beta.-Methylesculetin; NCGC00016349-01; Baogongteng B; 7-hydroxy-6-methoxy-chromen-2-one; KBio3_002444; NINDS_000720; 7-Hydroxy-5-methoxycoumarin; 7-hydroxy-6-methoxy-coumarin; Scopoletine; S2500_SIGMA; 7-hydroxy-6-methoxy-2H-chromen-2-one; CHEBI:17488; KBioGR_001348; SPBio_002884; Prestwick1_000962; NCGC00094973-01; 5-18-03-00203 (Beilstein Handbook Reference); EINECS 202-171-9; scopoletol; TNP00096; AIDS-014975; Gelseminic acid; DivK1c_000720; 6-O-Methylesculetin; Spectrum5_000654; Spectrum3_001532; 6-Methylesculetin; 2H-1-Benzopyran-2-one, 7-hydroxy-6-methoxy- (9CI); MEGxp0_001192; SPBio_000994; Scopoletin; 84792_FLUKA; IDI1_000720; COUMARIN, 7-HYDROXY-6-METHOXY-; 2H-1-Benzopyran-2-one, 7-hydroxy-6-methoxy-; ST056287; NCGC00094973-02; BRN 0156296; SPECTRUM1502242; Esculetin 6-methyl ether; BSPBio_002944; Chrysatropic acid; NCI60_003834; CAS-92-61-5; Prestwick3_000962; 7-hydroxy-6-methoxy-2-chromenone; Escopoletin; Spectrum2_001207; NCGC00094973-03; Murrayetin; 92-61-5; NSC405647; BSPBio_000963; NCGC00016349-02; KBio1_000720; 7-hydroxy-6-methoxychromen-2-one; Prestwick0_000962; 7-Hydroxy-6-methoxy-2H-1-benzopyran-2-one; C01752; ZINC00057733; AIDS014975; Prestwick2_000962; Spectrum4_001054; beta-Methylesculetin; ACon1_000143; BPBio1_001061; CCRIS 3592; 6-Methoxyumbelliferone; 7-Hydroxy-6-methoxycoumarin; .beta.-Methylesculetin; NCGC00016349-01; NSC 405647; 6-Methoxy-7-hydroxycoumarin; Esculetin-6-methyl ether; 6-methoxy-7-hydroxycoumarin; 7- hydroxy- 6-methoxy- coumarin; 6-methoxy-7-hydroxy coumarin; Scopoletol | C10H8O4 | 192.17 g/mol | COC1=C(C=C2C(=C1)C=CC(=O)O2)O |
| TCMBANKIN061574 | feruloyltyramine | n- cis-feruloyltyramine; NP-001984; (E)-3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; NCGC00169550-01; N-Trans-Feruloyl Tyramine; Moupinamide, >=95% (LC/MS-ELSD); 66648-43-9; Alfrutamide; trans-N-Feruloyltyramine; (E)-3-(4-Hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxy-phenyl)-ethyl]-acrylamide; N-Feruloyltyramine; ZINC901461; MEGxp0_000693; Feruloyltyramine; Moupinamide; BRD-K98045316-001-01-0; MolPort-001-740-847; 2-Propenamide, 3-(4-hydroxy-3-methoxyphenyl)-N-(2-(4-hydroxyphenyl)ethyl)-; MCULE-4768764740; n-trans-feruloyl-tyramine; W1092; (2E)-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; ACon1_001233; N-trans-Feruloyltyramine; (2,3)trans-N-(p-Hydroxyphenethyl)ferulamide; CHEMBL206555; 65646-26-6; n- trans-feruloyltyramine; N-Transferuloyl Tyramine; MFCD17214811; AKOS025287596; CHEBI:17818; C02717; AC1NQX6M; (E)-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; CHEBI:17818; 3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; (E)-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; AIDS113439; (2E)-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; 3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; (2,3)trans-N-(p-Hydroxyphenethyl)ferulamide; N-trans-Feruloyltyramine; C02717; (E)-3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]acrylamide; 3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]acrylamide; N-Feruloyltyramine; 65646-26-6; (E)-3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; AIDS-113439; 66648-43-9; Feruloyltyramine; moupinamide; 2-Propenamide, 3-(4-hydroxy-3-methoxyphenyl)-N-(2-(4-hydroxyphenyl)ethyl)-; ACon1_001233; (E)-3-(4-Hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxy-phenyl)-ethyl]-acrylamide; MEGxp0_000693; 2-Propenamide, 3-(4-hydroxy-3-methoxyphenyl)-N-(2-(4-hydroxyphenyl)ethyl)-, (2Z)-; 80510-09-4; (Z)-3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; (Z)-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; (Z)-3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]acrylamide; Moupinamide; n-trans-feruloyltyramine; N-E-feruloyl tyramine; n-cis-feruloyltyramine | C18H19NO4 | 313.3 g/mol | COC1=C(C=CC(=C1)C=CC(=O)NCCC2=CC=C(C=C2)O)O |
| TCMBANKIN061764 | Acanthoside B;(+)-Syringaresinol-O-beta-D-glucoside | ACon1_001107; (7alpha,7'alpha,8alpha,8'alpha)-4'-(beta-D-glucopyranosyloxy)-3,3',5,5'-tetramethoxy-7,9':7',9-diepoxylignan-4-ol; (2S,3R,4S,5S,6R)-2-[4-[(1S,3aR,4S,6aR)-4-(4-hydroxy-3,5-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[4,3-c]furan-1-yl]-2,6-dimethoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol; (2S,3R,4S,5S,6R)-2-[4-[(1S,3aR,4S,6aR)-4-(4-hydroxy-3,5-dimethoxy-phenyl)-1,3,3a,4,6,6a-hexahydrofuro[4,3-c]furan-1-yl]-2,6-dimethoxy-phenoxy]-6-methylol-tetrahydropyran-3,4,5-triol; 7374-79-0; (+)-syringaresinol beta-D-glucoside; (+)-Syringaresinol O-beta-D-glucoside; acanthoside b; C10890; (2S,3R,4S,5S,6R)-2-[4-[(1S,3aR,4S,6aR)-4-(4-hydroxy-3,5-dimethoxy-phenyl)-1,3,3a,4,6,6a-hexahydrofuro[4,3-c]furan-1-yl]-2,6-dimethoxy-phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol; beta-D-Glucopyranoside, 2,6-dimethoxy-4-(tetrahydro-4-(4-hydroxy-3,5-dimethoxyphenyl)-1H,3H-furo(3,4-c)furan-1-yl)phenyl, (1S-(1alpha,3aalpha,4a,6aalpha))-; (2S,3R,4S,5S,6R)-2-[4-[(1S,3aR,4S,6aR)-4-(4-hydroxy-3,5-dimethoxy-phenyl)-1,3,3a,4,6,6a-hexahydrofuro[4,3-c]furan-1-yl]-2,6-dimethoxy-phenoxy]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; CHEBI:28603; (2S,3R,4S,5S,6R)-2-[4-[(1S,3aR,4S,6aR)-4-(4-hydroxy-3,5-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[4,3-c]furan-1-yl]-2,6-dimethoxyphenoxy]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; MEGxp0_000366;(+)-syringaresinol-o-beta-d-glucopyranoside | C28H36O13 | 580.58 | COC1=CC(=CC(=C1O)OC)C2C3COC(C3CO2)C4=CC(=C(C(=C4)OC)OC5C(C(C(C(O5)CO)O)O)O)OC |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
植物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
|---|
滇ICP备16009434号-1 |
Dai SX Lab